- Home
- SOWG vs RDHL Comparison
SOWG vs RDHL Comparison
Compare SOWG & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SOWG | RDHL |
|---|---|---|
| Founded | 2010 | 2009 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.4M | 5.6M |
| IPO Year | 2011 | 2012 |
Fundamental Metrics
Financial Performance| Metric | SOWG | RDHL |
|---|---|---|
| Price | $0.47 | $0.97 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 59.9K | 34.5K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 32.20 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $31,992,511.00 | N/A |
| Revenue This Year | $6.81 | $381.91 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 99.07 | N/A |
| 52 Week Low | $0.23 | $0.91 |
| 52 Week High | $2.94 | $3.60 |
Technical Indicators
Market Signals| Indicator | SOWG | RDHL |
|---|---|---|
| Relative Strength Index (RSI) | 44.68 | 38.05 |
| Support Level | $0.23 | $0.91 |
| Resistance Level | $0.55 | $1.45 |
| Average True Range (ATR) | 0.05 | 0.07 |
| MACD | -0.00 | -0.00 |
| Stochastic Oscillator | 28.87 | 10.04 |
Price Performance
Historical ComparisonAbout SOWG Sow Good Inc.
Sow Good Inc is engaged in manufacturing and marketing freeze-dried fruits, vegetables, snacks, smoothies, and soups. The company also sells gluten-free products under the Sow Good brand. The company is developing a freeze-dried candy market and snack manufacturing to provide consumers with flavorful freeze-dried treats.
About RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.